Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Joseph J. Eron, Jr., MD, and Darcy Wooten, MD, share insights on HIV antiretroviral therapy safety and tolerability including recent data on weight gain and metabolic implications with INSTIs and NRTIs as well as the latest updates and recommendations on dolutegravir and pregnancy.
Joseph J. Eron, Jr., MD
Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California
From Dr. Eric Daar and CCO, slides covering new data from IAS 2021 expanding our understanding of the adverse event profiles of specific ART regimens
From Dr. Eric S. Daar and Clinical Care Options (CCO), expert discussion on how new data from IAS 2021 expand our understanding of adverse events with specific ART regimens
Dr Milena Murray and Clinical Care Options (CCO): ART-associated gestational weight gain, pregnancy effects, and the impact of baseline maternal weight
CCO slides from Dr. Colleen Kelley, on investigational long-acting HIV PrEP regimens in late stages of clinical development